New Oral COVID-19 Drug From Japan (S-217622)

S-217622 - Japan's COVID-19 Oral Drug Under Review for Approval

Shionogi's Ensitrelvir (S-217622) is an oral pill with 3CL/Mpro inhibitor mechanism. It is under review in Japan for COVID-19 management. Let's review its trial results/reports.
If you like this content and want more, I am doing a special lifetime membership offer. Click here:
https://www.drbeen.com/yt-special/

Want to support this work?:
Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
PayPal: https://paypal.me/mobeensyed?locale.x=en_US

My substack: https://mobeensyedmd.substack.com/

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

DrBeen: Continuing Medical Education Online | USMLE Prep | CME and CE marketplace | Nurse Practitioner and Physician Assistant Training Programs | Medical Student Training
https://www.drbeen.com/

URL list from Wednesday, Apr. 27 2022

DrBeen: Medical Education Online
https://www.drbeen.com/

Coronavirus biology and replication: implications for SARS-CoV-2 - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592455/

(A) Molecular surface representation of SARS-CoV-2 3CL pro with the... | Download Scientific Diagram
https://www.researchgate.net/figure/A-Molecular-surface-representation-of-SARS-CoV-2-3CL-pro-with-the-covalently-docked-hit_fig3_342304551

SARS-CoV-2 / COVID-19 Antibodies, Proteins, Kits | www.antibodies-online.com
https://www.antibodies-online.com/areas/infectious-disease/covid-19/

Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622 ｜Shionogi & Co., Ltd.
https://www.shionogi.com/global/en/news/2022/2/e-20220207.html

Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan | Shionogi & Co., Ltd.
https://www.shionogi.com/global/en/news/2022/2/220225.html

Notice Regarding the Media Coverage about S-217622, a Therapeutic Drug for COVID-19｜News｜Shionogi Co., Ltd.
https://www.shionogi.com/global/en/news/2022/04/e-20220413.html

Ensitrelvir | C22H17ClF3N9O2 - PubChem
https://pubchem.ncbi.nlm.nih.gov/compound/Ensitrelvir

Ensitrelvir, An Oral Antiviral Drug For COVID-19 Treatment | MolecularCloud
https://www.molecularcloud.org/p/ensitrelvir-an-oral-antiviral-drug-for-covid-19-treatment

Japan's Shionogi Says COVID Pill Shows Rapid Clearance of Virus
https://www.voanews.com/a/japan-shionogi-says-covid-pill-shows-rapid-clearance-of-virus/6543171.html

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus
https://news.yahoo.com/japans-shionogi-says-covid-19-112004466.html

Ensitrelvir - Wikipedia
https://en.wikipedia.org/wiki/Ensitrelvir

Coronavirus biology and replication: implications for SARS-CoV-2 - PubMed
https://pubmed.ncbi.nlm.nih.gov/33116300/

Huateng Pharma Supplies Ensitrelvir Intermeidates Against COVID-19 - Contract Pharma
https://www.contractpharma.com/csd/profile/hunan-huateng-pharmaceutical-co-ltd/view_huateng-pharma-supplies-ensitrelvir-intermeidates-/

shionogi « New Drug Approvals
https://newdrugapprovals.org/tag/shionogi/